Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice - Episode 7

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

July 13, 2023

Tina Cascone, MD, PhD, Sandip Patel, MD, Benjamin Levy, MD, David H. Harpole Jr, MD

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Early-Stage NSCLC and Molecular Testing

EP. 2: Selecting Optimal Treatment in Early-Stage NSCLC

EP. 3: Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

EP. 4: Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

EP. 5: Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

EP. 6: Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

Now Viewing

EP. 7: Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

EP. 8: Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

EP. 9: Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

EP. 10: Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

EP. 11: Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

EP. 12: Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

EP. 13: Practice Pearls for Community Oncologists Treating Early-Stage NSCLC